ClinicalTrials.gg

Program

Allogeneic Anti-BCMA CAR T-cells AZD4045

Its studies are mostly in Multiple Myeloma, led by AstraZeneca.

Furthest: phase 2, since Jun 26, 20261 company-led study, 1 open or runningNext primary completion: Mar 6, 2031 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 2since Jun 26, 2026Jun 26, 2026Mar 6, 2031phase 2 · NCT07681596
  • Named in AstraZeneca’s own pipeline as AZD4045, phase 1, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2026First study: phase 2 study in RecurrenceFirst studyNCT07681596 · 101 planned · United States, Australia

Ahead

  1. Mar 6, 2031Primary completion: phase 2 study in RecurrenceNCT07681596

TargetBeta

“A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential …”NCIt, read by Claude
“A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), ”NCIt, by rule

Other programs on TNFRSF17

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
belantamab mafodotinruleGlaxoSmithKlinephase 325
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 38
anitocabtagene autoleucelruleGilead Sciencesphase 36
equecabtagene autoleucelrulenanjing-iaso-biotechnology-co-ltdphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
Evarucabgene Autoleucelrulenexcella-incphase 32

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07681596Recurrence · United States, Australia2RecruitingMar 6, 2031101

How it is read

Names in the registry

  • “AZD4045”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.